CF Research Translation Center and Research Development Program
Seattle Children’s Research Institute
University of Washington
2001 8th Ave
Seattle, WA 98121

CF RDP Pilot Funding

Applications due AUGUST 15, 2017

Download Flyer

The UW Cystic Fibrosis Research Development Program (CF-RDP) is requesting Letters of Intent (one page maximum length) for Pilot and Feasibility (P&F) Projects to be funded starting 10/1/17. Basic science research projects will be funded at up to $50,000 (direct costs) per year for two years. Translational projects that make use of patient materials can be funded for up to $70,000 per year for two years. Translational research excludes exposing patients to experimental medicines and/or devices, using HIPAA protected patient information and using clinical samples obtained prospectively solely for the purposes of the translational project. No indirect costs are awarded.

These P&F funds are intended to support young investigators entering the CF research field; established investigators proposing CF research studies that are a significant departure from their previous or ongoing studies; or established investigators who have not been involved in CF research and propose to apply their expertise to the problems of CF.

Examples of relevant topics include but are not exclusive to:

    • Pulmonary inflammation
    • Pulmonary microbiology (e.g. P. aeruginosa)
    • Bacterial-epithelial cell interactions
    • Bacterial physiology and antibiotic resistance
    • CFTR structure/function
    • Lung transplantation

CFRTC Pilot Funding

Next RFA coming DECEMBER 2017

The NIH P30 Cystic Fibrosis Research Translation Center seeks applications for Pilot and Feasibility Studies focused on development and/or translation of promising laboratory findings that may lead to novel therapies for individuals with cystic fibrosis (CF).

Pilot and Feasibility applications are awarded every 2 years, for up to 2 years at $40,000 – $75,000 annual direct costs.  Investigators eligible for pilot and feasibility funding generally fall into three categories: (1) new investigators without current or past NIH research support as a principal investigator; (2) established investigators with no previous work in CF who wish to apply their expertise to a problem in this area; and (3) established investigators who propose testing innovative ideas that represent clear departure from ongoing research interests. Each pilot and feasibility proposal should state clearly the justification for eligibility of the investigator under one of the above three criteria.

Examples of relevant research topics are:

    1. Promote and expedite the translation of basic laboratory observations into a) better understanding of clinical disease b) improved diagnostic tools for assessing early disease manifestations in CF and/or c) new therapeutic approaches for treating gastrointestinal, hepatic, metabolic (including CF related diabetes mellitus) and lung disease in CF.
    2. Better understand the impact of bacterial genetic factors and phenotypic characteristics on progression of CF lung disease and GI health and utilize these findings to develop improved therapeutic approaches.
    3. Better understand host inflammatory responses to bacterial infection to optimize anti-inflammatory and anti-infective approaches.
    4. Better understand early infection in infants diagnosed with CF through newborn screening.

Applicants use standard PHS 398 forms for completing this application including face page, abstract, detailed budget and justification, biosketch, other support, resources, planned enrollment (for clinical studies) and research plan (limited to 5 pages not including references).

For further information, contact Bonnnie Ramsey, Pradeep Singh, or Donna Crist at